K.H. Lee

416 total citations
19 papers, 248 citations indexed

About

K.H. Lee is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Gastroenterology. According to data from OpenAlex, K.H. Lee has authored 19 papers receiving a total of 248 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 5 papers in Gastroenterology. Recurrent topics in K.H. Lee's work include Lung Cancer Treatments and Mutations (16 papers), Colorectal Cancer Treatments and Studies (6 papers) and Gastrointestinal Tumor Research and Treatment (5 papers). K.H. Lee is often cited by papers focused on Lung Cancer Treatments and Mutations (16 papers), Colorectal Cancer Treatments and Studies (6 papers) and Gastrointestinal Tumor Research and Treatment (5 papers). K.H. Lee collaborates with scholars based in South Korea, United States and Spain. K.H. Lee's co-authors include Myung‐Ju Ahn, Byoung Chul Cho, S.-H. Lee, Seo‐Young Park, Jin Seok Ahn, Jong‐Mu Sun, S.T. Kim, K. Park, Jin Hyoung Kang and Enriqueta Felip and has published in prestigious journals such as Annals of Oncology, European Journal of Cancer and Journal of Thoracic Oncology.

In The Last Decade

K.H. Lee

19 papers receiving 241 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
K.H. Lee South Korea 8 206 159 70 34 32 19 248
S. Korfee Germany 9 255 1.2× 206 1.3× 81 1.2× 20 0.6× 20 0.6× 15 326
M.C. Garassino Italy 5 327 1.6× 267 1.7× 71 1.0× 90 2.6× 15 0.5× 13 367
Silvia Buriolla Italy 6 99 0.5× 138 0.9× 57 0.8× 53 1.6× 15 0.5× 17 210
Diana Gernhardt United States 7 200 1.0× 248 1.6× 135 1.9× 56 1.6× 14 0.4× 8 338
Delan Li China 7 118 0.6× 134 0.8× 69 1.0× 39 1.1× 23 0.7× 13 195
Jiadi Gan China 11 183 0.9× 175 1.1× 93 1.3× 61 1.8× 9 0.3× 19 292
H. Akamatsu Japan 4 279 1.4× 211 1.3× 68 1.0× 89 2.6× 11 0.3× 10 314
Rossella Messina United States 3 233 1.1× 182 1.1× 75 1.1× 55 1.6× 10 0.3× 6 269
Daniele Presti Italy 7 75 0.4× 153 1.0× 49 0.7× 43 1.3× 16 0.5× 17 223
Masafumi Sata Japan 10 194 0.9× 202 1.3× 51 0.7× 12 0.4× 9 0.3× 25 283

Countries citing papers authored by K.H. Lee

Since Specialization
Citations

This map shows the geographic impact of K.H. Lee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K.H. Lee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K.H. Lee more than expected).

Fields of papers citing papers by K.H. Lee

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K.H. Lee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K.H. Lee. The network helps show where K.H. Lee may publish in the future.

Co-authorship network of co-authors of K.H. Lee

This figure shows the co-authorship network connecting the top 25 collaborators of K.H. Lee. A scholar is included among the top collaborators of K.H. Lee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K.H. Lee. K.H. Lee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Yang, James Chih‐Hsin, Paul Mitchell, Thomas John, et al.. (2023). 1325P Sunvozertinib as first-line treatment in NSCLC patients with EGFR Exon20 insertion mutations. Annals of Oncology. 34. S765–S765. 7 indexed citations
2.
Ahn, M-J., S-W. Kim, Enric Carcereny, et al.. (2022). LBA56 MEDI5752 or pembrolizumab (P) plus carboplatin/pemetrexed (CP) in treatment-naïve (1L) non-small cell lung cancer (NSCLC): A phase Ib/II trial. Annals of Oncology. 33. S1423–S1423. 15 indexed citations
3.
Cho, Byoung Chul, W. Marston Linehan, D. Ross Camidge, et al.. (2022). Pivotal topline data from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+ advanced non-small cell lung cancer (NSCLC). European Journal of Cancer. 174. S1–S2. 13 indexed citations
4.
Popat, Sanjay, Hye Ryun Kim, M-J. Ahn, et al.. (2021). 1195P Brigatinib (BRG) vs crizotinib (CRZ) in ALK TKI–naive ALK+ NSCLC: Final results from ALTA-1L. Annals of Oncology. 32. S954–S955. 1 indexed citations
5.
Haddish‐Berhane, Nahor, B.C. Cho, Myung‐Ju Ahn, et al.. (2021). P86.12 Cardiac Safety Assessment of Lazertinib in Patients with EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 16(3). S677–S678. 3 indexed citations
6.
Cho, B.C., Robert C. Doebele, W. Marston Linehan, et al.. (2021). MA11.07 Phase 1/2 TRIDENT-1 Study of Repotrectinib in Patients with ROS1+ or NTRK+ Advanced Solid Tumors. Journal of Thoracic Oncology. 16(3). S174–S175. 26 indexed citations
7.
8.
Ahn, M-J., Hye Ryun Kim, James Chih‐Hsin Yang, et al.. (2020). 1304P Brigatinib (BRG) vs crizotinib (CRZ) in Asian vs non-Asian patients (pts): Update from ALTA-1L. Annals of Oncology. 31. S843–S844. 1 indexed citations
9.
Paz‐Ares, Luis, David Vicente, Enriqueta Felip, et al.. (2020). 1272P Three-year follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, for second-line (2L) treatment of non-small cell lung cancer (NSCLC). Annals of Oncology. 31. S822–S822. 1 indexed citations
10.
Popat, Sanjay, Hye Ryun Kim, M-J. Ahn, et al.. (2020). 1300P Intracranial efficacy of brigatinib (BRG) vs crizotinib (CRZ): Updated results from the ALTA-1L trial. Annals of Oncology. 31. S840–S841. 2 indexed citations
11.
Camidge, D. Ross, Hye Ryun Kim, Myung‐Ju Ahn, et al.. (2019). Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: Updated results from the phase III ALTA-1L trial. Annals of Oncology. 30. ix195–ix196. 18 indexed citations
12.
Popat, Sanjay, Hye Ryun Kim, Myung‐Ju Ahn, et al.. (2018). Intracranial efficacy of brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial. Annals of Oncology. 29. viii746–viii746. 2 indexed citations
13.
Goss, Glenwood, Manuel Cobo, Shun Lü, et al.. (2018). Afatinib versus erlotinib as second-line treatment of patients (pts) with advanced lung squamous cell carcinoma (SCC): Final analysis of the global phase III LUX-Lung 8 (LL8) trial. Annals of Oncology. 29. viii521–viii521. 1 indexed citations
14.
Yu, Helena A., David Planchard, K.H. Lee, et al.. (2017). P1.04-001 Osimertinib with Ramucirumab or Necitumumab in Advanced T790M-positive EGFR-Mutant NSCLC: Preliminary Ph1 Study Results. Journal of Thoracic Oncology. 12(11). S1972–S1972. 5 indexed citations
15.
Goss, Glenwood, Enriqueta Felip, Manuel Cobo, et al.. (2017). P3.01-043 Impact of ErbB Mutations on Clinical Outcomes in Afatinib- or Erlotinib-Treated Patients with SCC of the Lung. Journal of Thoracic Oncology. 12(11). S2217–S2218. 2 indexed citations
16.
17.
18.
19.
Kim, J.S., et al.. (1996). Screening of antioxidative components from red ginseng saponin. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by S. Korfee Breakdown of academic impact, for papers by M.C. Garassino Breakdown of academic impact, for papers by Silvia Buriolla Breakdown of academic impact, for papers by Diana Gernhardt Breakdown of academic impact, for papers by Delan Li Breakdown of academic impact, for papers by Jiadi Gan Breakdown of academic impact, for papers by H. Akamatsu Breakdown of academic impact, for papers by Rossella Messina Breakdown of academic impact, for papers by Daniele Presti Breakdown of academic impact, for papers by Masafumi Sata
Rankless by CCL
2026